Solvay and Aqua Pharma link up to fight lice
Paramove producer Solvay and bath treatment dosing specialist Aquatiq have concluded a joint-venture agreement regarding Aquatiq Group company, Aqua Pharma. The companies said Solvay and Aqua Pharma aim to become a key aquaculture player by offering a wide range of sustainable and efficient solutions for sea lice control and amoebic gill disease (AGD) to the salmon industry.
Solvay and Aqua Pharma will put a strong focus on research and development, new products and new treatment methodology, and will further develop treatments for other fish species, Solvay said in a press release.
Aqua Pharma is investing in new treatment solutions and will provide a new technology for treatment using Solvay’s medical-grade hydrogen peroxide, Paramove, used to treat salmon for lice and AGD, from October. No further details were given of what the technology entails.
Combined expertise
“This JV agreement consolidates Solvay’s position in the aquaculture market” said Georges Crauser, president of the Solvay Peroxides global business unit. “Together, we believe that our combined expertise will bring value to the growing aquaculture industry in facing both challenges of fish health and environment protection with sustainable solutions.”
Aqua Pharma has been the exclusive distributor of Paramove for the last 10 years.
Accelerate development
It also has the largest Hydrolicer treatment unit, which offers a complementary sustainable solution to fight sea lice in Norway.
“This partnership with a company like Solvay, established in more than 60 countries, will allow us to accelerate our development to better serve customer needs around the globe,” said Aqua Pharma chief executive Elvin Bugge.
In the UK, Paramove is produced in Warrington and is distributed through the Aqua Pharma / Aquatiq business in Inverness.
